stockportfolio.pro
Stocks / HSIC vs KRYS
HSIC vs KRYS
Henry Schein, Inc. and Krystal Biotech, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Henry Schein, Inc. (HSIC) | Krystal Biotech, Inc. (KRYS) | |
|---|---|---|
| Market cap | $9.1B | $9.2B |
| Revenue (latest FY) | $13.18B | $389.13M |
| Net income (latest FY) | $398.00M | $204.83M |
| Revenue growth (5y CAGR) | 5.4% | — |
| Net margin | 3.0% | 52.6% |
| Return on equity | 12.3% | 16.8% |
| P/E ratio | 24.2 | 42.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HSIC — free Open KRYS — freeFrequently asked questions
Which is bigger, HSIC or KRYS?
Krystal Biotech, Inc. is larger by market capitalization — $9.2B versus $9.1B.
Which grows faster, HSIC or KRYS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.